{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:19:25Z","timestamp":1787066365524,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KUN 2014-6514"],"award-info":[{"award-number":["KUN 2014-6514"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n \n The current study explored the association between 2-[\n 18<\/jats:sup>\n F]fluoro-2-deoxy-D-glucose ([\n 18<\/jats:sup>\n F]FDG) uptake and the quantitative expression of immunohistochemical markers related to glucose metabolism, hypoxia, and cell proliferation in benign and malignant thyroid nodules of indeterminate cytology.\n <\/jats:p>\n <\/jats:sec>\n \n Procedures<\/jats:title>\n \n Using a case\u2013control design, 24 patients were selected from participants of a randomized controlled multicenter trial (NCT02208544) in which [\n 18<\/jats:sup>\n F]FDG-PET\/CT and thyroid surgery were performed for Bethesda III and IV nodules. Three equally sized groups of [\n 18<\/jats:sup>\n F]FDG-positive malignant, [\n 18<\/jats:sup>\n F]FDG-positive benign, and [\n 18<\/jats:sup>\n F]FDG-negative benign nodules were included. Immunohistochemical staining was performed for glucose transporters (GLUT) 1, 3, and 4; hexokinases (HK) 1 and 2; hypoxia-inducible factor-1 alpha (HIF1\u03b1; monocarboxylate transporter 4 (MCT4); carbonic anhydrase IX (CA-IX); vascular endothelial growth factor (VEGF); sodium-iodide symporter (NIS); and Ki-67. Marker expression was scored using an immunoreactive score. Unsupervised cluster analysis was performed. The immunoreactive score was correlated to the maximum and peak standardized uptake values (SUV\n max<\/jats:sub>\n , SUV\n peak<\/jats:sub>\n ) and SUV\n max<\/jats:sub>\n ratio (SUV\n max<\/jats:sub>\n of nodule\/background SUV\n max<\/jats:sub>\n of contralateral, normal thyroid) of the [\n 18<\/jats:sup>\n F]FDG-PET\/CT using the Spearman\u2019s rank correlation coefficient and compared between the three groups using Kruskal\u2013Wallis tests.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The expression of GLUT1, GLUT3, HK2, and MCT4 was strongly positively correlated with the SUV\n max<\/jats:sub>\n , SUV\n peak<\/jats:sub>\n , and SUV\n max<\/jats:sub>\n ratio. The expression of GLUT1 (\n p<\/jats:italic>\n \u2009=\u20090.009), HK2 (\n p<\/jats:italic>\n \u2009=\u20090.02), MCT4 (\n p<\/jats:italic>\n \u2009=\u20090.01), and VEGF (\n p<\/jats:italic>\n \u2009=\u20090.007) was statistically significantly different between [\n 18<\/jats:sup>\n F]FDG-positive benign nodules, [\n 18<\/jats:sup>\n F]FDG-positive thyroid carcinomas, and [\n 18<\/jats:sup>\n F]FDG-negative benign nodules. In both [\n 18<\/jats:sup>\n F]FDG-positive benign nodules and [\n 18<\/jats:sup>\n F]FDG-positive thyroid carcinomas, the expression of GLUT1, HK2, and MCT4 was increased as compared to [\n 18<\/jats:sup>\n F]FDG-negative benign nodules. VEGF expression was higher in [\n 18<\/jats:sup>\n F]FDG-positive thyroid carcinomas as compared to [\n 18<\/jats:sup>\n F]FDG-negative and [\n 18<\/jats:sup>\n F]FDG-positive benign nodules.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Our results suggest that [\n 18<\/jats:sup>\n F]FDG-positive benign thyroid nodules undergo changes in protein expression similar to those in thyroid carcinomas. To expand the understanding of the metabolic changes in benign and malignant thyroid nodules, further research is required, including correlation with underlying genetic alterations.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s11307-022-01776-4","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T16:35:25Z","timestamp":1666024525000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["[18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8111-1172","authenticated-orcid":false,"given":"Elizabeth J.","family":"de Koster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3154-3601","authenticated-orcid":false,"given":"Adriana C. H.","family":"van Engen-van Grunsven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-4796","authenticated-orcid":false,"given":"Johan","family":"Bussink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathelijne","family":"Frielink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-2743","authenticated-orcid":false,"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"Kusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4353-8970","authenticated-orcid":false,"given":"Hans","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8235-7078","authenticated-orcid":false,"given":"Wim J. G.","family":"Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-6766","authenticated-orcid":false,"given":"Dennis","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the EFFECTS trial study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana T.","family":"Netea-Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan W. A.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H. W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Booij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamira K.","family":"Klooker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline W. C. M.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen M. A.","family":"Dreijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter G. H. M.","family":"Raijmakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boen L. R.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Verzijlbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten O.","family":"van Aken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet L.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Sophie","family":"Mijnhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert B.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M. Pereira","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Morreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Snel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioe-Ting","family":"Dijkhorst-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M. H.","family":"de Klerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Havekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Cristina","family":"Mitea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"V\u00f6\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine B.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter S.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferida","family":"Sivro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik T.","family":"te Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max C. W.","family":"Jebbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gysele S.","family":"Bleumink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa J. R.","family":"Schelfhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth G. M.","family":"Keijsers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M. M. J.","family":"Wakelkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne H.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thera P.","family":"Links","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"de Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"van Leeuwaarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes J.","family":"Bonenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Rogier T.","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen J.","family":"F\u00fctterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"1776_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1776_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211\u2013218","journal-title":"Trends Biochem Sci"},{"key":"1776_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12020-020-02239-y","volume":"69","author":"A Piccardo","year":"2020","unstructured":"Piccardo A, Puntoni M, Dezzana M et al (2020) Indeterminate thyroid nodules. The role of (18)F-FDG PET\/CT in the \u201cera\u201d of ultrasonography risk stratification systems and new thyroid cytology classifications. Endocrine 69:553\u2013561","journal-title":"Endocrine"},{"key":"1776_CR4","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s00259-014-2774-y","volume":"41","author":"A Piccardo","year":"2014","unstructured":"Piccardo A, Puntoni M, Bertagna F et al (2014) 18F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET\/CT: a multicentre study. Eur J Nucl Med Mol Imaging 41:1482\u20131491","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1776_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4158\/EP-2017-0080","volume":"24","author":"P Santhanam","year":"2018","unstructured":"Santhanam P, Khthir R, Solnes LB, Ladenson PW (2018) The relationship of BRAF(V600e) mutation status to FDG PET\/CT avidity in thyroid cancer: a review and meta-analysis. Endocr Pract 24:21\u201326","journal-title":"Endocr Pract"},{"key":"1776_CR6","first-page":"1","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Dai H, Li Q, Shen G, Shi L, Tian R (2021) Investigating (18)F-FDG PET\/CT parameters as prognostic markers for differentiated thyroid cancer: a systematic review. Front Oncol 11:1\u20139","journal-title":"Front Oncol"},{"key":"1776_CR7","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1245\/s10434-010-1469-2","volume":"18","author":"JW Choi","year":"2011","unstructured":"Choi JW, Yoon YH, Yoon YH, Kim SM, Koo BS (2011) Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET\/CT. Ann Surg Oncol 18:1306\u20131311","journal-title":"Ann Surg Oncol"},{"key":"1776_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2017.0500","volume":"27","author":"ES Cibas","year":"2017","unstructured":"Cibas ES, Ali SZ (2017) The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 27:1341\u20131346","journal-title":"Thyroid"},{"key":"1776_CR9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1007\/s00259-021-05627-2","volume":"49","author":"EJ de Koster","year":"2022","unstructured":"de Koster EJ, de Geus-Oei LF, Brouwers AH et al (2022) [18F]FDG-PET\/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. Eur J Nucl Med Mol Imaging 49:1970\u20131984","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1776_CR10","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2967\/jnumed.114.137034","volume":"55","author":"A van Berkel","year":"2014","unstructured":"van Berkel A, Rao JU, Kusters B et al (2014) Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med 55:1253\u20131259","journal-title":"J Nucl Med"},{"key":"1776_CR11","doi-asserted-by":"publisher","first-page":"e0217781","DOI":"10.1371\/journal.pone.0217781","volume":"14","author":"HJ Meyer","year":"2019","unstructured":"Meyer HJ, Wienke A, Surov A (2019) Associations between GLUT expression and SUV values derived from FDG-PET in different tumors-a systematic review and meta analysis. PLoS One 14:e0217781","journal-title":"PLoS One"},{"key":"1776_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2006.08.018","volume":"55","author":"LF de Geus-Oei","year":"2007","unstructured":"de Geus-Oei LF, van Krieken JH, Aliredjo RP et al (2007) Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55:79\u201387","journal-title":"Lung Cancer"},{"key":"1776_CR13","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1089\/thy.2013.0051","volume":"23","author":"MH Kim","year":"2013","unstructured":"Kim MH, Ko SH, Bae JS et al (2013) Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma. Thyroid 23:1452\u20131460","journal-title":"Thyroid"},{"key":"1776_CR14","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00259-008-0758-5","volume":"35","author":"RA Dierckx","year":"2008","unstructured":"Dierckx RA, Van de Wiele C (2008) FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 35:1544\u20131549","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1776_CR15","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1007\/s00259-008-0888-9","volume":"35","author":"M Busk","year":"2008","unstructured":"Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J (2008) Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 35:2294\u20132303","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1776_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/JTO.0000000000000286","volume":"9","author":"OC Schuurbiers","year":"2014","unstructured":"Schuurbiers OC, Meijer TW, Kaanders JH et al (2014) Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol 9:1485\u20131493","journal-title":"J Thorac Oncol"},{"key":"1776_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12253-017-0232-4","volume":"24","author":"A Klaus","year":"2018","unstructured":"Klaus A, Fathi O, Tatjana TW, Bruno N, Oskar K (2018) Expression of hypoxia-associated protein HIF-1alpha in follicular thyroid cancer is associated with distant metastasis. Pathol Oncol Res 24:289\u2013296","journal-title":"Pathol Oncol Res"},{"key":"1776_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1010428317695922","volume":"39","author":"JH Nahm","year":"2017","unstructured":"Nahm JH, Kim HM, Koo JS (2017) Glycolysis-related protein expression in thyroid cancer. Tumour Biol 39:1\u201310","journal-title":"Tumour Biol"},{"key":"1776_CR19","doi-asserted-by":"publisher","first-page":"6230294","DOI":"10.1155\/2017\/6230294","volume":"2017","author":"HM Kim","year":"2017","unstructured":"Kim HM, Koo JS (2017) Differential expression of glycolysis-related proteins in follicular neoplasms versus hurthle cell neoplasms: a retrospective analysis. Dis Markers 2017:6230294","journal-title":"Dis Markers"},{"key":"1776_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.lungcan.2011.11.006","volume":"76","author":"TW Meijer","year":"2012","unstructured":"Meijer TW, Schuurbiers OC, Kaanders JH et al (2012) Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer 76:316\u2013323","journal-title":"Lung Cancer"},{"key":"1776_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MNM.0000000000000019","volume":"35","author":"H Kaida","year":"2014","unstructured":"Kaida H, Kawahara A, Hayakawa M et al (2014) The difference in relationship between 18F-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancers. Nucl Med Commun 35:36\u201343","journal-title":"Nucl Med Commun"},{"key":"1776_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/RLU.0b013e3182393599","volume":"37","author":"F Grabellus","year":"2012","unstructured":"Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY (2012) Glucose transporter 1 expression, tumor proliferation, and iodine\/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 37:121\u2013127","journal-title":"Clin Nucl Med"},{"key":"1776_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/105072503321669866","volume":"13","author":"P Kjellman","year":"2003","unstructured":"Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zedenius J (2003) MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 13:371\u2013380","journal-title":"Thyroid"},{"key":"1776_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00268-009-0344-4","volume":"34","author":"A Itoh","year":"2010","unstructured":"Itoh A, Iwase K, Jimbo S et al (2010) Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World J Surg 34:242\u2013248","journal-title":"World J Surg"},{"key":"1776_CR25","first-page":"4010","volume":"60","author":"HE Ryan","year":"2000","unstructured":"Ryan HE, Poloni M, McNulty W et al (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60:4010\u20134015","journal-title":"Cancer Res"},{"key":"1776_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1210\/jc.2004-0779","volume":"90","author":"L Hooft","year":"2005","unstructured":"Hooft L, van der Veldt AA, van Diest PJ et al (2005) [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab 90:328\u2013334","journal-title":"J Clin Endocrinol Metab"},{"key":"1776_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2013.11.025","volume":"83","author":"K Kaira","year":"2014","unstructured":"Kaira K, Serizawa M, Koh Y et al (2014) Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 83:197\u2013204","journal-title":"Lung Cancer"},{"key":"1776_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/EJE-19-0261","volume":"181","author":"W Qichang","year":"2019","unstructured":"Qichang W, Lin B, Gege Z et al (2019) Diagnostic performance of 18F-FDG-PET\/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol 181:93\u2013102","journal-title":"Eur J Endocrinol"},{"key":"1776_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/thy.2011.0311","volume":"22","author":"I Kollecker","year":"2012","unstructured":"Kollecker I, von Wasielewski R, Langner C et al (2012) Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues. Thyroid 22:529\u2013535","journal-title":"Thyroid"},{"key":"1776_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s13139-013-0249-x","volume":"48","author":"S Kim","year":"2014","unstructured":"Kim S, Chung JK, Min HS et al (2014) Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nucl Med Mol Imaging 48:91\u201397","journal-title":"Nucl Med Mol Imaging"},{"key":"1776_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/MNM.0b013e32834754f1","volume":"32","author":"H Kaida","year":"2011","unstructured":"Kaida H, Hiromatsu Y, Kurata S et al (2011) Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer. Nucl Med Commun 32:690\u2013698","journal-title":"Nucl Med Commun"},{"key":"1776_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3109\/07435800.2015.1066803","volume":"41","author":"M Yoon","year":"2016","unstructured":"Yoon M, Jung SJ, Kim TH et al (2016) Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Endocr Res 41:64\u201369","journal-title":"Endocr Res"},{"key":"1776_CR33","first-page":"309","volume":"25","author":"BH Kim","year":"2010","unstructured":"Kim BH, Kim IJ, Kim SS, Kim SJ, Lee CH, Kim YK (2010) Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Cancer Biother Radiopharm 25:309\u2013315","journal-title":"Cancer Biother Radiopharm"},{"key":"1776_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/MNM.0b013e32835e59ee","volume":"34","author":"C Lansoy-Kuhn","year":"2013","unstructured":"Lansoy-Kuhn C, Picquenot JM, Edet-Sanson A et al (2013) Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET\/CT at recurrence in patients with well-differentiated thyroid carcinoma. Nucl Med Commun 34:340\u2013346","journal-title":"Nucl Med Commun"},{"key":"1776_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mce.2008.05.003","volume":"291","author":"R Ciampi","year":"2008","unstructured":"Ciampi R, Vivaldi A, Romei C et al (2008) Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol 291:57\u201362","journal-title":"Mol Cell Endocrinol"},{"key":"1776_CR36","first-page":"1499","volume":"14","author":"M Yasuda","year":"2005","unstructured":"Yasuda M, Ogane N, Hayashi H et al (2005) Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep 14:1499\u20131504","journal-title":"Oncol Rep"},{"key":"1776_CR37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-018-1627-z","volume":"61","author":"N Mu","year":"2018","unstructured":"Mu N, Juhlin CC, Tani E et al (2018) High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma. Endocrine 61:293\u2013302","journal-title":"Endocrine"},{"key":"1776_CR38","volume-title":"WHO classification of tumours of endocrine organs. WHO classification of tumours","author":"RV Lloyd","year":"2017","unstructured":"Lloyd RV, Osamura RY, Kl\u00f6ppel G, Rosai J (2017) WHO classification of tumours of endocrine organs. WHO classification of tumours, 4th edn. IARC, Lyon, France","edition":"4"},{"key":"1776_CR39","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138\u2013140","journal-title":"Pathologe"},{"key":"1776_CR40","first-page":"2349","volume":"14","author":"J Demsar","year":"2013","unstructured":"Demsar J, Curk T, Erjavec A et al (2013) Orange: data mining toolbox in Python. J Mach Learn Res 14:2349\u20132353","journal-title":"J Mach Learn Res"},{"key":"1776_CR41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1089\/thy.2004.14.806","volume":"14","author":"K Matsuzu","year":"2004","unstructured":"Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND (2004) Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 14:806\u2013812","journal-title":"Thyroid"},{"key":"1776_CR42","first-page":"129","volume":"53","author":"I Lewy-Trenda","year":"2002","unstructured":"Lewy-Trenda I, Wierzchniewska-Lawska A (2002) Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors. Pol J Pathol 53:129\u2013132","journal-title":"Pol J Pathol"},{"key":"1776_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2265.2011.04032.x","volume":"75","author":"EC Morari","year":"2011","unstructured":"Morari EC, Marcello MA, Guilhen AC et al (2011) Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol (Oxf) 75:247\u2013254","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1776_CR44","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/modpathol.2010.86","volume":"23","author":"M Zerilli","year":"2010","unstructured":"Zerilli M, Zito G, Martorana A et al (2010) BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. Mod Pathol 23:1052\u20131060","journal-title":"Mod Pathol"},{"key":"1776_CR45","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2967\/jnumed.109.062331","volume":"50","author":"O Prante","year":"2009","unstructured":"Prante O, Maschauer S, Fremont V et al (2009) Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med 50:1364\u20131370","journal-title":"J Nucl Med"},{"key":"1776_CR46","first-page":"59","volume":"54","author":"F Morani","year":"2012","unstructured":"Morani F, Pagano L, Prodam F, Aimaretti G, Isidoro C (2012) Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas associates with GLUT1 plasmamembrane expression. Panminerva Med 54:59\u201363","journal-title":"Panminerva Med"},{"key":"1776_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12964-020-00586-x","volume":"18","author":"S Heydarzadeh","year":"2020","unstructured":"Heydarzadeh S, Moshtaghie AA, Daneshpoor M, Hedayati M (2020) Regulators of glucose uptake in thyroid cancer cell lines. Cell Commun Signal 18:83","journal-title":"Cell Commun Signal"},{"key":"1776_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/thy.2021.0424","volume":"32","author":"D Matsuura","year":"2022","unstructured":"Matsuura D, Yuan A, Wang LY et al (2022) Follicular and hurthle cell carcinoma: comparison of clinicopathological features and clinical outcomes. Thyroid 32:245\u2013254","journal-title":"Thyroid"},{"key":"1776_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1530\/ERC-17-0288","volume":"25","author":"WE Corver","year":"2018","unstructured":"Corver WE, Demmers J, Oosting J et al (2018) ROS-induced near-homozygous genomes in thyroid cancer. Endocr Relat Cancer 25:83\u201397","journal-title":"Endocr Relat Cancer"},{"key":"1776_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/ERC-20-0435","volume":"28","author":"WR Doerfler","year":"2021","unstructured":"Doerfler WR, Nikitski AV, Morariu EM et al (2021) Molecular alterations in Hurthle cell nodules and preoperative cancer risk. Endocr Relat Cancer 28:301\u2013309","journal-title":"Endocr Relat Cancer"},{"key":"1776_CR51","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s12149-016-1087-6","volume":"30","author":"KA Pathak","year":"2016","unstructured":"Pathak KA, Klonisch T, Nason RW, Leslie WD (2016) FDG-PET characteristics of Hurthle cell and follicular adenomas. Ann Nucl Med 30:506\u2013509","journal-title":"Ann Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01776-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T03:49:12Z","timestamp":1683776952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01776-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01776-4","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The EfFECTS<\/i> trial, including the current study, was approved by the Medical Research Ethics Committee on Research Involving Human Subjects region Arnhem-Nijmegen, Nijmegen, the Netherlands on 10 November 2014.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Prior to any study activities, written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All patients signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}